XNASSLDB
Market cap130mUSD
Jan 17, Last price
3.27USD
1D
0.62%
1Q
-50.45%
IPO
-99.08%
Name
Solid Biosciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
55.07%
Rev. gr., 5y
%
Revenues
0k
-100.00%
Net income
-96m
L+46.57%
CFO
-94m
L-3.88%
Earnings
Mar 11, 2025
Profile
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 8,094 -40.57% | ||||||||
Cost of revenue | 180,878 | 109,776 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (180,878) | (101,682) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (20,471) | ||||||||
Tax Rate | |||||||||
NOPAT | (180,878) | (81,211) | |||||||
Net income | (96,015) 46.57% | (65,510) -9.17% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 2,974 | 72,551 | |||||||
BB yield | -2.44% | -158.43% | |||||||
| Debt | |||||||||
Debt current | 4,648 | 2,565 | |||||||
Long-term debt | 50,206 | 54,529 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 96 | ||||||||
Net debt | (68,786) | (158,461) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (94,180) | (97,977) | |||||||
CAPEX | (1,515) | (3,015) | |||||||
Cash from investing activities | 9,689 | 59,157 | |||||||
Cash from financing activities | 3,122 | 74,831 | |||||||
FCF | (175,435) | (112,213) | |||||||
| Balance | |||||||||
Cash | 123,640 | 213,722 | |||||||
Long term investments | 1,833 | ||||||||
Excess cash | 123,640 | 215,150 | |||||||
Stockholders' equity | (658,718) | (562,786) | |||||||
Invested Capital | 813,788 | 803,095 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 19,884 | 8,512 | |||||||
Price | 6.14 14.13% | 5.38 -79.50% | |||||||
Market cap | 122,088 166.60% | 45,795 -75.49% | |||||||
EV | 53,302 | (112,666) | |||||||
EBITDA | (178,297) | (99,274) | |||||||
EV/EBITDA | 1.13 | ||||||||
Interest | 20,471 | ||||||||
Interest/NOPBT | |||||||||